Personal stories

The company’s ability to evolve as it tackles the world’s toughest health challenges has helped Johnson & Johnson earn its spot as the top-ranked healthcare company on the list.

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

The power of partnership, asking questions and speaking up: insights from bladder cancer patients and a caregiver on living with intention after diagnosis.

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

New global survey findings reveal the often unseen emotional, mental and daily-life impact of living with bladder cancer.

Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.